Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 166

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 166
---
 policy as expressed in the Securities       
 Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by          
 the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of          
 any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,  
 the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate 
 jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be          
 governed by the final adjudication of such issue.                                                                                                |

| II-3 |

| (c) | The undersigned registrant hereby undertakes that: |

| (1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from                                   
 the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed 
 by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration    
 statement as of the time it was declared effective.                                                                                        |

| (2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment                          
 that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and 
 the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.                            |

| II-4 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Cardiff, Wales, on this 8 day of December, 2025.

| BIODEXA PHARMACEUTICALS PLC |                         |
| By:                         | /s/ Stephen Stamp       |
|                             | Stephen Stamp           |
|                             | Chief Executive Officer |

Pursuant to the requirements of the Securities
Act of 1933,